ClinicalTrials.gov
ClinicalTrials.gov Menu

Effects of Aging and Aerobic Exercise Training on Brain Glucose Metabolism

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01738568
Recruitment Status : Active, not recruiting
First Posted : November 30, 2012
Last Update Posted : July 19, 2017
Sponsor:
Information provided by (Responsible Party):
Val Lowe, Mayo Clinic

Brief Summary:
Aging is associated with a loss of brain function and conditions such as dementia and Alzheimer's disease. It is likely that decreased brain metabolism is contributing to the progression of age related degenerative diseases. Aerobic exercise training can increase brain volumes and is associated with decreased risk for degenerative brain conditions. However, little is know about the changes that occur to brain metabolism with aerobic training and aging.

Condition or disease Intervention/treatment Phase
Dementia Behavioral: High intensity aerobic training Behavioral: Sedentary Control Not Applicable

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Effect of Aging and Aerobic Exercise Training on Brain Glucose Metabolism
Study Start Date : October 2012
Estimated Primary Completion Date : June 2019
Estimated Study Completion Date : December 2019

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: Exercise
Aerobic exercise
Behavioral: High intensity aerobic training
High intensity aerobic interval training will be performed 12-weeks. Exercise training will last 1 hour per day, 5 days per week and include high intensity interval cycling at ~70-95% maximum workload for 4 minutes followed by 3 minutes of rest.
Behavioral: Sedentary Control
Sedentary control participants will not perform any regular exercise for 12-weeks.



Primary Outcome Measures :
  1. Change in Brain Glucose Uptake [ Time Frame: 12 weeks ]
    The investigators will assess brain glucose uptake using positron emission tomography at baseline and following 12-weeks of either aerobic exercise training or sedentary control period.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Healthy sedentary adults aged 18-30 or 65-80 years of all ethnicities will be eligible. Pregnant women, children, prisoners or other at risk populations will not be recruited.

Inclusion Criteria:

  • Age 18-30 years or 65-80 years

Exclusion Criteria:

  • Body mass index (BMI) >31 kg/m2
  • Smoking
  • Pregnancy
  • Participation in structured exercise (>2 times per week for 30 minutes or longer)
  • Cardiovascular, metabolic (type 2 diabetes, fasting plasma glucose at or above 110 mg/dL and untreated hypo- or hyperthyroidism) or renal disease
  • Orthopedic problems that would keep them from being able to ride an exercise bicycle, lift weights or do a combination of these exercise
  • Medications that are known to impact on mitochondrial function: Corticosteroids, opiates, benzodiazepines, tricyclic antidepressants, beta blockers, sulfonylureas, insulin, anticoagulants, barbiturates, insulin sensitizers, fibrates (PPAR gamma agonist)
  • Claustrophobia

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01738568


Locations
United States, Minnesota
Mayo Clinic in Rochester
Rochester, Minnesota, United States, 55905
Sponsors and Collaborators
Mayo Clinic
Investigators
Principal Investigator: Val Lowe, MD Mayo Clinic

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Val Lowe, PI, Mayo Clinic
ClinicalTrials.gov Identifier: NCT01738568     History of Changes
Other Study ID Numbers: 12-003357
First Posted: November 30, 2012    Key Record Dates
Last Update Posted: July 19, 2017
Last Verified: July 2017

Keywords provided by Val Lowe, Mayo Clinic:
High intensity aerobic training

Additional relevant MeSH terms:
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurocognitive Disorders
Mental Disorders